Heart Disease News and Research

Latest Heart Disease News and Research

New Cordis device granted Humanitarian Exemption to treat intracranial aneurysms

Cordis Neurovascular, Inc. has announced that the U.S. Food and Drug Administration has granted Humanitarian Device Exemption (HDE) approval for the CORDIS ENTERPRISE Vascular Reconstruction Device and Delivery System for use with embolic coils in the treatment of wide-neck intracranial aneurysms.

10 May 2007

One-third to nearly one-half of all children and adolescents should be tested for cholesterol levels

According to the AHA, the physicians who care for these at-risk youth face an unexpected obstacle -- their parents. The AHA finds "low levels of parental compliance with both cholesterol screening and intervention."

10 May 2007

Omega-3 fatty acids may lower risk of Alzheimer's

Nutritionists have long endorsed fish as part of a heart-healthy diet, and now some studies suggest that omega-3 fatty acids found in the oil of certain fish may also benefit the brain by lowering the risk of Alzheimer's disease.

10 May 2007

Human papillomavirus linked to throat cancers

Researchers at the Johns Hopkins Kimmel Cancer Center have conclusive evidence that human papillomavirus (HPV) causes some throat cancers in both men and women.

10 May 2007

Frequent urination often indicates an underlying medical condition

An increase in the number of trips to the bathroom - day or night - is a signal it's time to see a physician.

10 May 2007

Discovery of cellular processes which regulate heart's energy supply

The heart needs a steady supply of energy to function properly. MUHC researcher Dr. Vincent Gigure's and his colleagues recently identified several genetic programs which work together to ensure this energy is available.

10 May 2007

Heart failure patients should be thoroughly evaluated for the presence of diabetes

New research from UAB (University of Alabama at Birmingham) shows that the effect of diabetes on the severity of illness and risk of death for patients with heart failure is much worse in women than men.

10 May 2007

Coarse particulate matter in outdoor air raises bad cholesterol

Breathing air containing coarse particulate matter such as road or construction dust may cause heart problems for asthma sufferers and other vulnerable populations, according to a new study led by the University of North Carolina at Chapel Hill School of Public Health.

10 May 2007

Structural variation in the human genome

A major new effort to uncover the medium- and large-scale genetic differences between humans may soon reveal DNA sequences that contribute to a wide range of diseases, according to a paper by Howard Hughes Medical Institute investigator Evan Eichler and 17 colleagues published in the May 10, 2007, Nature.

10 May 2007

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb Company and Isis Pharmaceuticals have announced a collaboration to discover, develop and commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for the prevention and treatment of cardiovascular disease.

10 May 2007

Recent developments for drug-eluting stents

Drug-eluting stents -- small metal tubes used to prop open clogged arteries -- have been garnering headlines.

10 May 2007

Sigma-Aldrich acquires Molecular Medicine BioServices

Sigma-Aldrich Corporation has announced that it has acquired Molecular Medicine BioServices Inc. (MMB), a biopharmaceutical contract manufacturing organization (CMO) located in Carlsbad, California, to further enhance the biologics capabilities within its SAFC Pharma business segment.

9 May 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Off-label and untested use of drug-coated stents is common in U.S. practice

The off-label and untested use of drug-coated stents in the treatment of coronary artery blockage is common in U.S. practice, and ischemic complication rates are higher among patients receiving drug-coated stents for off-label indications, according to two studies in the May 9 issue of Journal of the American Medical Association.

9 May 2007

Adverse outcomes associated with unapproved uses of drug-coated stents

Research led by a team at the Methodist DeBakey Heart Center sheds light on what happens to high-risk patients who receive drug-coated stents off-label to open clogged arteries, as reported in today's Journal of the American Medical Association (JAMA) .

9 May 2007

Global heartbeat control suggests therapy for beating heart failure

Keeping a healthy heart beating requires the production of a constant supply of energy, a feat depending on the coordination of several genetic programs.

9 May 2007

Plant chemical harmine fights diabetes in mice

After screening hundreds of compounds for their effects on fat development, researchers have discovered that an ingredient found in some plants fights diabetes in mice without some of the side effects attributed to other antidiabetes drugs.

9 May 2007

Baby aspirin better for your health

Nearly a quarter of a million Americans each year may be hospitalized with bleeding complications caused by needlessly taking a daily dose of an adult-sized aspirin rather than a baby aspirin to prevent a heart attack or stroke.

9 May 2007

Ischemic-targeted approach to angioplasty among asymptomatic survivors of heart attack

When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with "silent ischemia", according to a study in the May 9 issue of Journal of the American Medical Association.

9 May 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007